These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1334 related articles for article (PubMed ID: 31817676)

  • 1. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations.
    Magaway C; Kim E; Jacinto E
    Cells; 2019 Dec; 8(12):. PubMed ID: 31817676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the mTOR pathway in tumor malignancy.
    Cheng H; Walls M; Baxi SM; Yin MJ
    Curr Cancer Drug Targets; 2013 Mar; 13(3):267-77. PubMed ID: 23297825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting mTOR for cancer therapy.
    Hua H; Kong Q; Zhang H; Wang J; Luo T; Jiang Y
    J Hematol Oncol; 2019 Jul; 12(1):71. PubMed ID: 31277692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug discovery targeting the mTOR pathway.
    Martelli AM; Buontempo F; McCubrey JA
    Clin Sci (Lond); 2018 Mar; 132(5):543-568. PubMed ID: 29523752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
    Chen SM; Liu JL; Wang X; Liang C; Ding J; Meng LH
    Biochem Pharmacol; 2012 May; 83(9):1183-94. PubMed ID: 22305748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR kinase inhibitors as potential cancer therapeutic drugs.
    Sun SY
    Cancer Lett; 2013 Oct; 340(1):1-8. PubMed ID: 23792225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer.
    Evangelisti C; Chiarini F; Paganelli F; Marmiroli S; Martelli AM
    Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118635. PubMed ID: 31884070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
    Zou Z; Chen J; Yang J; Bai X
    Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updates of mTOR inhibitors.
    Zhou H; Luo Y; Huang S
    Anticancer Agents Med Chem; 2010 Sep; 10(7):571-81. PubMed ID: 20812900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current treatment strategies for inhibiting mTOR in cancer.
    Chiarini F; Evangelisti C; McCubrey JA; Martelli AM
    Trends Pharmacol Sci; 2015 Feb; 36(2):124-35. PubMed ID: 25497227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy.
    Tian T; Li X; Zhang J
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30754640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
    Alzahrani AS
    Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations.
    Moschetta M; Reale A; Marasco C; Vacca A; Carratù MR
    Br J Pharmacol; 2014 Aug; 171(16):3801-13. PubMed ID: 24780124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
    Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
    Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-generation Inhibitors and Approaches.
    Ihlamur M; Akgul B; Zengin Y; Korkut ŞV; Kelleci K; Abamor EŞ
    Curr Mol Med; 2024; 24(4):478-494. PubMed ID: 37165594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [mTOR complexes -- molecular spiders in molecular networks].
    Kopper L; Tímár J
    Magy Onkol; 2011 Nov; 55(4):287-94. PubMed ID: 22128312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR in Lung Neoplasms.
    Krencz I; Sebestyen A; Khoor A
    Pathol Oncol Res; 2020 Jan; 26(1):35-48. PubMed ID: 32016810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.